The ADC market offers significant growth opportunities driven by the rising cancer incidence and demand for targeted therapies, which improve efficacy and reduce toxicity. Advancements in precision ...

A new HIC–MS method using ammonium tartrate improves ADC characterization, enabling efficient drug-to-antibody ratio analysis without complex workflows. A proteomics workflow combining laser ablation ...

Genentech's native HIC-MS method uses ammonium tartrate, enabling efficient MS detection without compromising chromatographic ...

ADC conjugation, redefined. Explore a rapid 3-hour workflow that delivers precise, controlled antibody-drug conjugates for ...

Discover the innovative Alco5 platform by Tubulis, advancing cancer therapies with novel antibody-drug conjugate technology.

Ellipses and Innolake will collaborate closely on the development of ILB-3101/EP0028, which is currently in a Phase 1 trial in China sponsored by Innolake. Ellipses will initiate a Phase 1 clinical ...

COLORADO SPRINGS, CO, UNITED STATES, January 14, 2026 /EINPresswire.com/ -- Lahjavida Bio, a biotechnology company ...

Advances in lung cancer treatment have changed survival in ways that were unimaginable even a decade ago. Targeted drugs, ...

According to doctors and hospital officials, these drugs incur 8 to 12 per cent import duties, and the basic customs duty tax ...

Ellipses Pharma Limited (“Ellipses”), a clinical-stage oncology drug development company with a pipeline of innovative programmes, announced that it has entered into a collaboration and licence ...

The exemption of basic customs duty on 17 cancer drugs and the addition of seven rare diseases to the list eligible for duty-free personal imports have been widely described as a patient-first reform.

The company joins a group of degrader ADC (or DAC) developers that includes Bristol Myers Squibb and Pfizer.